COMMUNIQUÉS West-GlobeNewswire

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
28/01/2026
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB [...]
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
28/01/2026
Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel Approach to Targeted, Pressure-Mediated Drug-Delivery via Additional Clinical Data MOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE [...]
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
28/01/2026
This cross-disciplinary meeting highlights the latest discoveries, technologies and translational strategies driving the next generation of antimicrobial solutions JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- [...]
Autonomix Medical to Present Final Analysis on Pain Mitigation in Pancreatic Cancer at SIO 2026 Annual Scientific Meeting
28/01/2026
THE WOODLANDS, TX, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies
28/01/2026
IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trials BOSTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Life Biosciences , Inc., (“Life Bio”) a [...]
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
28/01/2026
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and [...]
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
28/01/2026
BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
28/01/2026
RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, [...]
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
28/01/2026
Nugevia ™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss Jupiter, Florida, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” [...]
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
28/01/2026
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues [...]
Vireo Growth Inc. Enters into Non-Binding Memorandum of Understanding to Acquire The Hawthorne Gardening Company from ScottsMiracle-Gro
28/01/2026
Planned share-based transaction is expected to be completed during the first fiscal quarter of 2026 Vireo plans to appoint Chris Hagedorn to its Board of Directors MINNEAPOLIS, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vireo [...]
Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss
28/01/2026
-- Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient recombinases with Lilly’s extensive development expertise in genetic [...]
Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site
28/01/2026
BOSTON and STOCKHOLM, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mabtech, a global life science tools company specializing in advanced immunoassays, and Sai Life Sciences, a leading integrated Contract Research, Development, and [...]
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
28/01/2026
Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People [...]
DXS International plc (AQSE: DXSP): Half-year Financial Report
28/01/2026
DXS INTERNATIONAL PLC (AQSE: DXSP) HALF YEAR RESULTS DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to provide shareholders with its unaudited interim results [...]
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
28/01/2026
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activity Litifilimab has the [...]
OMass Therapeutics Appoints Jonathan Montagu as Chair of the Board of Directors
28/01/2026
OXFORD, United Kingdom, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins [...]
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
28/01/2026
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases Interim data from additional [...]
OKYO Pharma Announces Successful Type C Meeting with the FDA
28/01/2026
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approach LONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage [...]

Pages